thalidomide has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 13 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide is often used in the maintenance setting for multiple myeloma and has been linked to the development of secondary primary malignancies." | 3.85 | Lenalidomide and secondary acute lymphoblastic leukemia: a case series. ( Fong, R; Lo, M; Tan, M; Young, R, 2017) |
| " Here, we report the success of thalidomide treatment for 2 subtypes of histiocytic proliferation--metastatic histiocytic sarcoma and extracutaneous juvenile xanthogranuloma--in pediatric patients." | 3.78 | Thalidomide therapy for aggressive histiocytic lesions in the pediatric population. ( Bailey, KM; Castle, VP; Hummel, JM; McAllister-Lucas, LM; Moyer, J; Piert, M, 2012) |
| "Lenalidomide was given orally at escalating doses of 25 to 75 mg daily on days 1 through 21 of 28-day cycles to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD), as well as to provide pharmacokinetic and preliminary efficacy data." | 2.75 | Dose escalation of lenalidomide in relapsed or refractory acute leukemias. ( Becker, H; Blum, W; Byrd, JC; Chandler, JC; Curfman, J; Devine, SM; Garzon, R; Grever, MR; Kefauver, C; Klisovic, RB; Liu, S; Marcucci, G; Mickle, J; Phelps, MA; Rozewski, DM; Schaaf, L; Walker, A; Whitman, SP; Yang, X, 2010) |
| "Acute lymphoblastic leukemia (ALL) is a hematological disorder involving at least 20% lymphoblasts in the bone marrow of the B-cell lineage." | 1.39 | Acute myelofibrosis and acute lymphoblastic leukemia in an elderly patient with previously treated multiple myeloma. ( Chen, L; Gonzalez, MM; Kidd, L; Nguyen, N; Quesada, J, 2013) |
| "Thalidomide is a drug with anti-angiogenic, anti-inflammatory, immunomodulatory and anti-cancer properties that were found to inhibit the production of TNF-alpha in vitro, stimulate reactive oxygen species production, and inhibit VEGFR in acute leukemias." | 1.33 | Ex vivo activity of thalidomide in childhood acute leukemia. ( Czyzewski, K; Styczynski, J; Wysocki, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-Muñoz, R | 1 |
| Robles-de-Castro, D | 1 |
| Muñoz-Rodríguez, A | 1 |
| Rabasa, P | 1 |
| Gonzalez, MM | 1 |
| Kidd, L | 1 |
| Quesada, J | 1 |
| Nguyen, N | 1 |
| Chen, L | 1 |
| Nair, R | 1 |
| Gheith, S | 1 |
| Popescu, D | 1 |
| Agostino, NM | 1 |
| Tan, M | 1 |
| Fong, R | 1 |
| Lo, M | 1 |
| Young, R | 1 |
| Tavernier-Tardy, E | 1 |
| Cornillon, J | 1 |
| Molucon-Chabrot, C | 1 |
| Cahn, JY | 1 |
| Tinquaut, F | 1 |
| Bourmaud, A | 1 |
| Guyotat, D | 1 |
| Thomas, X | 1 |
| Stefan, DC | 1 |
| Andronikou, S | 1 |
| Freeman, N | 1 |
| Schoeman, J | 1 |
| Blum, W | 1 |
| Klisovic, RB | 1 |
| Becker, H | 1 |
| Yang, X | 1 |
| Rozewski, DM | 1 |
| Phelps, MA | 1 |
| Garzon, R | 1 |
| Walker, A | 1 |
| Chandler, JC | 1 |
| Whitman, SP | 1 |
| Curfman, J | 1 |
| Liu, S | 1 |
| Schaaf, L | 1 |
| Mickle, J | 1 |
| Kefauver, C | 1 |
| Devine, SM | 1 |
| Grever, MR | 1 |
| Marcucci, G | 1 |
| Byrd, JC | 1 |
| Chan, TS | 1 |
| Au, WY | 1 |
| Lam, K | 1 |
| Lam, YF | 1 |
| So, CC | 1 |
| Leung, AY | 1 |
| Tse, E | 1 |
| Lie, AK | 1 |
| Kwong, YL | 1 |
| Bailey, KM | 1 |
| Castle, VP | 1 |
| Hummel, JM | 1 |
| Piert, M | 1 |
| Moyer, J | 1 |
| McAllister-Lucas, LM | 1 |
| Ribatti, D | 1 |
| Scavelli, C | 1 |
| Roccaro, AM | 1 |
| Crivellato, E | 1 |
| Nico, B | 1 |
| Vacca, A | 1 |
| Styczynski, J | 1 |
| Czyzewski, K | 1 |
| Wysocki, M | 1 |
| Shalapour, S | 1 |
| Zelmer, A | 1 |
| Pfau, M | 1 |
| Moderegger, E | 1 |
| Costa-Blechschmidt, C | 1 |
| van Landeghem, FK | 1 |
| Taube, T | 1 |
| Fichtner, I | 1 |
| Bührer, C | 1 |
| Henze, G | 1 |
| Seeger, K | 1 |
| Wellmann, S | 1 |
| Lopez, J | 1 |
| Ulibarrena, C | 1 |
| Garcia-Laraña, J | 1 |
| Odriozola, J | 1 |
| Pérez de Oteyza, J | 1 |
| Sastre, JL | 1 |
| Navarro, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions[NCT03113942] | Phase 2 | 26 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thalidomide and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; | 2013 |
Hematopoietic cancer and angiogenesis.
Topics: Angiogenesis Inhibitors; Cell Proliferation; Disease Progression; Endothelium, Vascular; Hematologic | 2004 |
2 trials available for thalidomide and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
A phase 1/2 trial of lenalidomide and dexamethasone in adult patients with refractory/relapsed acute lymphoblastic leukemia.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy | 2017 |
Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplas | 2010 |
9 other studies available for thalidomide and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Acute myelofibrosis and acute lymphoblastic leukemia in an elderly patient with previously treated multiple myeloma.
Topics: Aged; Blood Cell Count; Bone Marrow; Humans; Immunohistochemistry; Lenalidomide; Maintenance Chemoth | 2013 |
A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Birefringence | 2014 |
Lenalidomide and secondary acute lymphoblastic leukemia: a case series.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Humans; Immunologic Factors; Lenalidomide; Male; Middle | 2017 |
Recovery of vision after adjuvant thalidomide in a child with tuberculous meningitis and acute lymphoblastic leukemia.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Blindness; Brain; Chemother | 2009 |
Donor cell leukaemia after allogeneic haematopoietic SCT followed by prolonged thalidomide maintenance for multiple myeloma.
Topics: Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Living Donors; Ma | 2012 |
Thalidomide therapy for aggressive histiocytic lesions in the pediatric population.
Topics: Adolescent; Child; Female; Histiocytic Sarcoma; Humans; Immunosuppressive Agents; Michigan; Precurso | 2012 |
Ex vivo activity of thalidomide in childhood acute leukemia.
Topics: Angiogenesis Inhibitors; Cell Cycle; Child; Child, Preschool; Cytarabine; Female; Humans; Immunophen | 2006 |
The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo.
Topics: Animals; Apoptosis; Blood Vessels; Caspase 3; Cell Proliferation; Child, Preschool; Female; Humans; | 2006 |
Thalidomide as therapy for intestinal chronic GVHD.
Topics: Adult; Bone Marrow Transplantation; Graft vs Host Disease; Humans; Intestinal Diseases; Male; Precur | 1993 |